期刊文献+

前列腺癌组织BSP和PSA的表达及意义 被引量:2

Expressions of Bone Sialoprotein and Prostate-specific Antigen in Prostate Cancer and Their Significance
原文传递
导出
摘要 [目的]探讨骨唾液酸蛋白(BSP)与前列腺特异性抗原(PSA)在前列腺癌组织中的表达及意义。[方法]选取不同病理分级的前列腺癌组织(68例)和前列腺增生组织(22例),采用免疫组织化学SP法染色,检测BSP及PSA的表达情况。[结果]BSP在前列腺癌中阳性率为76.47%,显著高于前列腺增生组织(13.64%)(χ2=27.614,P<0.001)。BSP在不同分化程度前列腺癌组织中表达差异无统计学意义(χ2=0.057,P=0.972)。前列腺增生组织、前列腺癌组织的PSA表达率分别为90.91%、69.12%,差异有统计学意义(χ2=4.149,P=0.042)。不同分化程度前列腺癌PSA表达差异有统计学意义(χ2=11.437,P=0.003)。BSP与PSA表达具有显著相关性(rs=0.654,P<0.001)。[结论]BSP在前列腺癌中高表达,与PSA表达相关。BSP可能在前列腺癌的发生、发展中起重要作用,可能成为前列腺癌治疗的新靶点。 [Purpose] To investigate the expressions of bone sialoprotein (BSP) and prostate-specific antigen (PSA) in prostate cancer and their significance. [Methods] The expressions of BSP and PSA in 68 cases of prostate cancer with various pathological grading and in 22 cases with benign prostatic hyperplasia were detected immunohistochemically. [ Results ] The expression rate of BSP in prostate cancer (76.47%) was significantly higher than that in benign prostatic hyperplasia (13.64%)(χ^2=27.614, P〈0.001 ). There was no significant difference of BSP expression in prostate cancer patients with various pathological grades (χ^2=0.057, P=0.972). The expression rate of PSA in prostate cancer and in benign prostatic hyperplasia was 69.12% and 90.91% ,with sig- nificant difference between them (χ^2=4.149, P=0.042). There was significant difference of PSA expression in prostate cancer patients with various pathological grades (χ^2=11.437 ,P=0.003). Posi- tive correlation was found between BSP and PSA (r=0.654, P〈0.001 ). [ Conclusion ] The high expression of BSP in prostate cancer is related to the expression of PSA.BSP may play an important role in the oneogenesis and progress of prostate cancer, and it may be as a new target for prostate cancer treatment.
出处 《肿瘤学杂志》 CAS 2014年第9期755-757,共3页 Journal of Chinese Oncology
基金 海南省卫生基金资助项目(琼卫2011-98号)
关键词 前列腺肿瘤 骨唾液酸蛋白 前列腺特异性抗原 免疫组织化学 prostate neoplasms bone sialoprotein (BSP) prostate-specific antigen (PSA) immunohistochemistry
  • 相关文献

参考文献7

  • 1Li Z , Wang Z, Yang L, et aI.Fibroblast growth factor 2 regulates bone siaIoprotein gene transcription in human breast cancer cells[J].J Oral Sci,2010,52(1): 125-132.
  • 2Ogata Y.Bone sialoprotein and its transcriptional regulatory mechanism[J].J Periodontal Res,2008,43(2): 127-135.
  • 3Tu Q ,Zhang J ,Fix A,et aI.Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells[J].J Cell Physiol, 2009,218(1): 135-145.
  • 4Waltregny D,Bellahcene A,de LevaI X,et al. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers[J]. J Bone Miner Res,2000, 15(5):834-843.
  • 5Bellahcene A, Menard S, Bufalino R, et al.Expression of bone siaIopromin in primary human breast cancer is associated with poor survival[J].Cancer, 1996,69(4): 350-353.
  • 6江先汉,黄海,何慧婵,江福能,钟惟德.前列腺特异性抗原在前列腺癌中的诊断价值[J].肿瘤学杂志,2011,17(3):237-238. 被引量:13
  • 7邹永浩,周荣祥,杨明军,刘胜荣,胡正禾,宫振安.前列腺癌组织FHIT和PSA表达的初步研究[J].中华肿瘤防治杂志,2008,15(9):687-689. 被引量:5

二级参考文献11

  • 1周桥.前列腺癌Gleason分级[J].中华病理学杂志,2005,34(4):240-243. 被引量:44
  • 2叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 3胡志全.PSA生物化学的研究进展[J].国外医学(泌尿系统分册),1996,16(5):195-198. 被引量:10
  • 4[1]Parkin D M,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J C1in,2005,55:74-108.
  • 5[4]Ohta M,Inoue H,Cotticelli M G,et al.The FHIT gene,spanning the chromosome 3p14.2 fragile site and renal carcinoma associated t (3;8) breakpoint,is abnormal in digestive tract cancers[J].cell,1996,84(4):587-597.
  • 6Heather P, Cornford P. Prostate-specific antigen:an evoloving role in diagnosis, monitoring and treatment evaluation in prostate cancer[J]. J Urologic Oncol, 2010, 6(1):1-9.
  • 7Oesterling JE, Jacobsen S J, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age specific reference ranges[J]. JAMA, 1993, 270(7):860-864.
  • 8Pienta KJ. Critical appraisal of prostate specific antigen in prostate cancer screening: 20 years later[J]. Urology, 2009, 72(5):s11-s20.
  • 9Thompson M, Pauler DK, Goodman PJ,et al. Prevalence of prostate cancer among men with a prostate-specific anti- gen level ≤4.0ng permilliliter [J]. N Engl J Med, 2004, 350(22):2239-2246.
  • 10Ouyang B, Bracken B, Burke B, et al. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer[J]. J Urol, 2009, 181 (6):2508-2513.

共引文献16

同被引文献24

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部